Atrium Therapeutics Reports Third Quarter 2026 Financial Results
-- First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome -- -- Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome -- -- Pro-forma cash balance at the end of September 2026 was $293.6...
Covered in this story
Call it yourself
No calls on $ATR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AptarGroup →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.